Inmed PharmaceuticalsINM
13F holders, Q2 2025 (June 30)7holders +2
2new positions
0sold out
$3.37avg. 13F price*
At the end of Q2 2025, 7 institutions reported holding Inmed Pharmaceuticals Inc. (INM) in their 13F filings, up 2 from Q1 2025. 2 opened new positions and 0 sold out. The largest holders were UBS Group AG ($25K), Tower Research Capital LLC (TRC) ($1K) and Banque Cantonale Vaudoise ($1K).
- Company
- Inmed Pharmaceuticals Inc.
- CUSIP
- 457637700
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $1K |
| Exits | 0 | $0 |
All 13F filers, Q1 2025 → Q2 2025: 2,057 shares bought, net +2,057 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 7 holders
| UBS Group AG | 0.00% | Add +27.1% | 7,762 | $25K |
| Tower Research Capital LLC (TRC) | 0.00% | New | 400 | $1K |
| Banque Cantonale Vaudoise | 0.00% | No change | 6 | $1K |
| SBI Securities Co., Ltd. | 0.00% | No change | 300 | $975 |
| AllSquare Wealth Management LLC | 0.00% | No change | 1 | $3 |
| Federation des caisses Desjardins du Quebec | 0.00% | No change | 1 | $3 |
| Bessemer Group Inc. | 0.00% | New | 1 | $0 |
"% of holder's portfolio" is INM's weight in each manager's 13F, not the share of Inmed Pharmaceuticals Inc. the manager owns.